A Phase 3 interventional study of risperidone; quetiapine in Bipolar Disorder, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Completed. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2011-05-24.
Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (part of Johnson & Johnson) · Phase 3 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing risperidone in Bipolar Disorder — none open to participants now, none under way, none of them phase 3. Risperidone · Bipolar Disorder.
Among the 29 studies testing risperidone in Bipolar Disorder, this one is the 25th largest by enrollment, is one of 7 that started in 2004, is one of 16 in phase 3, and was the 4th registered.
1,686 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.
Browse Bipolar Disorder studies →None of the 29 studies testing risperidone in Bipolar Disorder is open now. The open studies under Bipolar Disorder, anywhere →
Risperidone: first FDA approval 1993 (RISPERDAL), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 7 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 64 across 1,281 interventional studies indexed under Bipolar Disorder.
Median enrollment 78 across the 29 interventional studies. Of the 29 that completed or were terminated, 9 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 29 have an industry lead sponsor. The 10 most frequent:
This study is registered under Johnson & Johnson Pharmaceutical Research & Development, L.L.C., one of the names counted as Johnson & Johnson. Under that name alone:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. is the lead sponsor of 465 studies on the registry; none are open to participants now.
39 studies in Bipolar Disorder by Johnson & Johnson: 2 open now, 2 under way, 2 of them phase 3. Of 37 finished, 9 (24%) have results posted.
Among the 39 studies in Bipolar Disorder by Johnson & Johnson, this one is the 33rd largest by enrollment of the 36 interventional ones that give a count, is one of 4 that started in 2004, is one of 28 in phase 3, and was the 6th registered.
Johnson & Johnson’s Bipolar Disorder studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 29 studies testing risperidone in Bipolar Disorder, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 39 in Bipolar Disorder:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether the sedating (causing sleepiness) effects of risperidone or quetiapine alter cognitive (person's ability to think, perceive, recognize, remember, judge, and reason) functioning in subjects with stable Bipolar I Disorder.
To compare the treatment effects of risperidone and quetiapine on cognitive function, using measures commonly believed to be affected by sedation and at doses typically used in clinical settings in stable bipolar I outpatients.One-half of patients are randomized to treatment sequence risperidone-quetiapine (R-Q), and the other one-half to quetiapine-risperidone (Q-R). Patients randomized to R-Q receive 2 mg of risperidone with dinner the night before testing and placebo with breakfast on the day of testing. After a 6 - 14 day washout period they receive 100 mg quetiapine with dinner the night before their second day of testing and 100 mg with breakfast the day of testing.
Those randomized to Q-R receive the same treatments, but in reverse order. Patients randomized to R-Q receive 2 mg of risperidone with dinner the night before testing and placebo with breakfast on the day of testing. After a 6-14 day washout period they receive 100 mg quetiapine with dinner the night before their second day of testing and 100 mg with breakfast the day of testing. Those randomized to Q-R receive the same treatments, but in reverse order.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug pages: RisperidoneStudies of RisperidoneRisperidone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · QuetiapineStudies of QuetiapineQuetiapine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
To compare the treatment effects of risperidone and quetiapine on cognitive function due to sedation
To assess the association between subjective experience of sedation and cognitive function
No study locations are listed for this record.
The record gives a start of Oct 2004 and a completion of May 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Risperidone · Quetiapine
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. →